联合吸入噻托溴铵和布地奈德混悬液治疗COPD的疗效观察

目的观察联合吸入噻托溴铵及布地奈德混悬液治疗COPD。方法呼吸内科住院COPD患者60例,(男42例,女18例),按照随机数字表法分为三组:(1)联合治疗组20例,吸入噻托溴铵干粉胶囊1粒(18μg),经单剂量干粉吸入器,每日上午1次,吸入布地奈德混悬液,通过DRT型小型雾化器,剂量每次1 mg,1天2次。(2)布地奈德雾化液吸入组,20例,吸入布地奈德混悬液,剂量每次1 mg,1天2次。(3)空白对照组20例,疗程2周。结果试验组在第一周以后,吸入沙丁胺醇前的FEV1均明显高于空白对照组,一直持续到第二周,联合治疗组的FEV1升高明显高于布地奈德组。实验结束时,联合治疗组的FEV1提高了10.3%,布地奈德组提高了8.2%。空白对照组改变不明显。差异均有统计学意义。结论吸入型长效抗胆碱能药物联合长效激素制剂治疗COPD,在控制症状、改善肺功能方面均优于单独使用激素,及空白对照组。本试验未发现有更多的不良反应,其安全性能够被接受。

Combination of inhaled tiotropium and budesonide suspension in the treatment observation of chronic obstructive pulmonary disease

Objective To observe the efficacy of combination therapy of inhaled tiotropium and budesonide suspension in improving lung function and health status in the treatment of COPD. Methods 60 patients with COPD were treated in randomised-groups,controlled study with tiotropium （ 18 μg） once daily and budesonide suspension （ 1 mg） twice daily （ n = 20 ） ; Budesonide suspension （ 1 rag） twice daily（ n = 20）. Patients in the blank controlled group （n = 20）did not receive any inhaled anticholinergic drugs, long-acting B2 agonists or glucocortieoid therapy. The period of treatment was two weeks. Results After one week,The FEV1 in the controlled study with tiotropium and budesonide suspension was significantly improved （ 10. 3% ） compared to the budesonide suspension group： an 8.2% increased, which was gloater than the blank group. Conclusion Combination of inhaled tiotropium and budesonide suspension in the treatment of chronic obstructive pulmonary disease leads to better control of symptoms and improve of lung function ,with no greater risk of sideeffects,as compared to budesonide suspension group or usual treatment.